A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).

Sehhoon Park,Yun-Gyoo Lee,Ji Hyun Park,Gyeong-Won Lee,Eun Joo Kang,Yoon Ji Choi,SeongHoon Shin,Ji Youn Han,Suee Lee,Y Kim,Tae Min Kim,Sang-We Kim,Byoung-Yong Shim,Jinhyun Cho,Hye-Sook Kim,Sang Gon Park,Ki Hyeong Lee,Il-Hwan Kim,Myung-Ju Ahn

A phase III, open-label, randomized study of atezolizumab in combination with carboplatin + paclitaxel + bevacizumab compared with pemetrexed + cisplatin or carboplatin with stage IV non-squamous non-small cell lung cancer (NSCLC) with activating EGFR mutation or ALK translocation (ATLAS Trial).

2020

Sehhoon Park
Yun-Gyoo Lee
Ji Hyun Park
Gyeong-Won Lee
Eun Joo Kang
Yoon Ji Choi
SeongHoon Shin
Ji Youn Han
Suee Lee
Y Kim
Tae Min Kim
Sang-We Kim
Byoung-Yong Shim
Jinhyun Cho
Hye-Sook Kim
Sang Gon Park
Ki Hyeong Lee
Il-Hwan Kim
Myung-Ju Ahn

TPS9636Background: In patients with activating EGFR mutations and ALK fusion, target specific tyrosine kinase inhibitor (TKI) showed significant survival improvement compared to the cytotoxic chemo...

Keywords:

Cisplatin
Atezolizumab
Pemetrexed
Bevacizumab
Carboplatin
Pathology
open label
non-small cell lung cancer (NSCLC)
Randomized controlled trial
Medicine
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations